Navigation Links
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Date:1/12/2009

PRINCETON, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that they and their development partner, Roche, have agreed with the FDA on the final design for a phase 2b trial with R7128, a nucleoside inhibitor of hepatitis C (HCV), slated to initiate in the first quarter of this year.

"We are pleased that R7128 is advancing into a large phase 2b trial," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "R7128 is the most advanced nucleoside polymerase inhibitor in development and we believe this class of drug brings a number of advantages to HCV-infected patients. R7128's higher barrier to resistance and activity across multiple viral genotypes, as well as the promising short-term safety and tolerability, may bring patients a new option for therapy. We look for this trial to better define the optimal treatment duration with R7128 in combination with the standard of care."

The phase 2b trial is anticipated to enroll about 400 treatment naive, genotype-1 or genotype 4 HCV-infected patients. The trial will evaluate the dose and duration of treatment of R7128 in combination with Pegasys(R) plus Copegus(R). The primary efficacy endpoint of the trial will be the proportion of patients that achieve a sustained virologic response (SVR), defined as undetectable (measured by Roche TaqMan assay) HCV RNA 24 weeks after completion of treatment. Patients will be enrolled into one of 5 arms:

  • 24 weeks of total treatment, with R7128 500mg bid in combination with pegylated interferon and ribavirin for 12 weeks, followed by 12 weeks of pegylated interferon and ribavirin
  • 24 weeks of total treatment, with R7128 1000mg bid in combination with pegylated interferon and ribavirin for 12 weeks, followed by 12 weeks of pegylated interferon
    '/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
3. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
4. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
5. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
8. Pharmasset Joins Russell 3000 Index
9. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
10. Pharmasset Selected to Join the NASDAQ Biotechnology Index
11. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... September 30, 2014 Award winning ... announces four new-hosted collaboration bundles that combine ... high quality conferencing experiences for low, flat rate ... choose from, businesses have optimized solutions to meet ... include audio only minutes (1K, 5K, 10K ...
(Date:10/1/2014)... The U.S. Department of Labor has awarded ... as part of the Trade Adjustment Assistance Community College ... by the Department of Labor and Department of Education. ... E. Perez and Secretary of Education Arne Duncan announced ... to nearly 270 colleges across the country. , ...
(Date:9/30/2014)... in German . ... dots in a semiconductor layer. Quantum dots are small structures ... If a short laser pulse is fired at the photonic ... experiences a change in the electromagnetic field around it. This ... light by the dot. As soon as the refractive index ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Ultrafast remote switching of light emission 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3
... CARLOS, Calif., Sept. 16 Nektar,Therapeutics, (Nasdaq: NKTR ... scheduled to present at the upcoming UBS 2008 Global ... New York Hotel on,Tuesday, September 23, 2008 at 10:30 ... a Webcast through a link posted,on the Investor Relations, ...
... Claims, WASHINGTON, Sept. 16 The U.S. ... to the State of Kentucky to,help defray costs ... may prove actual innocence. Awarded by the DOJ,s ... of five competitive awards provided to,Arizona, Texas, Virginia, ...
... 16 PharmAthene, Inc.,(Amex: PIP ) a ... threats, announced today that David P. Wright,President and ... the,UBS Global Life Sciences Conference on September 25, ... Grant Hyatt hotel in New York., PharmAthene,s ...
Cached Biology Technology:Department of Justice Provides States With Funding for Testing in Postconviction Cases 2
(Date:9/30/2014)... do seedless watermelon, salmon, and strawberries all have in ... two sets of chromosomes and are diploid, these organisms ... sets of chromosomesseedless watermelon and salmon have 3 and ... While this might seem surprising, in fact most ... first discovered over a century ago, but only recently, ...
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
(Date:9/30/2014)... German . FRANKFURT. ... in the world. Because they grow underground, people use trained ... of truffles is not only of interest to gourmets. A ... the Goethe University Frankfurt have discovered that the smell of ... trapped inside truffle fruiting bodies. , White truffles from the ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Researchers get $5.25 million to advance nuclear technologies in South Carolina 2On the trail of the truffle flavor 2
... have designated a group of 13 ... (leishmaniasis), African Sleeping Sickness (African trypanosomiasis), ... Filariasis (elephantiasis), Onchocerciasis (river blindness), Drancunculiasis ... Ulcer, Trachoma). , These diseases have ...
... inserted into blood vessels, to better deliver beneficial genes ... of inflammation that often negates initial benefits. The new ... thin layer to bare metal surfaces, may have potential ... of metallic implants. , Cardiologists frequently treat heart disease ...
... An international team of scientists for the first time ... after it has encountered a single, new stimulus. The ... to peer within the living brain and explore short-term ... Galán, a leading author on the report who is ...
Cached Biology News:A New Era of Hope for the World's Most Neglected Diseases 2A New Era of Hope for the World's Most Neglected Diseases 3Bare metal stents deliver gene therapy to heart vessels with less inflammation in animal studies 2Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace 2Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace 3
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Biology Products: